Joint damage is amplified in rheumatoid arthritis patients with positive thyroid autoantibodies

Rheumatoid Arthritis

Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity

Front Immunol.

Arntz OJ, Pieters BCH, Thurlings RM, Wenink MH, van Lent PLEM, Koenders MI, van den Hoogen FHJ, van der Kraan PM, van de Loo FAJ

doi: 10.3389/fimmu.2018.02388.

OsteoarthritisPsoriatic ArthritisRheumatoid Arthritis

Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis

Ann Rheum Dis

Gessl I, Popescu M, Schimpl V, Supp G, Deimel T, Durechova M, Hucke M, Loiskandl M, Studenic P, Zauner M, Smolen JS, Aletaha D, Mandl P

doi: 10.1136/annrheumdis-2020-218744

Rheumatoid ArthritisFurther Publications Rheumatology

MRI detected synovitis of the small joints predicts rheumatoid arthritis development in large joint undifferentiated inflammatory arthritis

Rheumatology (Oxford)

Sidhu N, Wouters F, Niemantsverdriet E, van der Helm-van Mil AHM

doi: 10.1093/rheumatology/keab515

Juvenile Idiopathic ArthritisRheumatoid ArthritisSpinal Disorders

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial

Arthritis Res Ther

Stockfelt M, Lundell AC, Hetland ML, Østergaard M, Uhlig T, Heiberg MS, Haavardsholm EA, Nurmohamed MT, Lampa J, Nordström D, Petersen KH, Gudbjornsson B, Gröndal G, Aldridge J, Andersson K, Blennow K, Zetterberg H, van Vollenhoven R, Rudin A

doi: 10.1186/s13075-021-02556-1

Rheumatoid Arthritis

Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.

Arthritis Res Ther.

Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD

Rheumatoid Arthritis

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

Clin Rheumatol.

van der Heijde D, Durez P, Schett G, Naredo E, Østergaard M, Meszaros G, De Leonardis F, de la Torre I, López-Romero P, Schlichting D, Nantz E, Fleischmann R

doi: 10.1007/s10067-018-4221-0.

Rheumatoid Arthritis

Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND

J Rheumatol

van der Heijde D, Kartman CE, Xie L, Beattie S, Schlichting D, Mo D, Durez P, Tanaka Y, Fleischmann R

doi: 10.3899/jrheum.210346

Rheumatoid Arthritis

Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status

Ann Rheum Dis.

Boeters DM, Burgers LE, Toes RE, van der Helm-van Mil A

doi: 10.1136/annrheumdis-2018-214868.

Rheumatoid Arthritis

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry

Rheumatol Ther.

Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V

doi: 10.1007/s40744-017-0077-z.

Related content

Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity

Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis

MRI detected synovitis of the small joints predicts rheumatoid arthritis development in large joint undifferentiated inflammatory arthritis

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial

Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND

Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry